Specificity of antinuclear autoantibodies recognizing the dense fine speckled nuclear pattern: Preferential targeting of DFS70/LEDGFp75 over its interacting partner MeCP2
Submitted by Greisha Lee Ortiz Hernandez on
PDF version| Title | Specificity of antinuclear autoantibodies recognizing the dense fine speckled nuclear pattern: Preferential targeting of DFS70/LEDGFp75 over its interacting partner MeCP2 |
| Publication Type | Journal Article |
| Year of Publication | 2015 |
| Authors | Basu, A, Woods-Burnham, L, Ortiz, G, Rios-Colon, L, Figueroa, J, Albesa, R, Andrade, LE, Mahler, M, Casiano, CA |
| Journal | Clin ImmunolClin ImmunolClin Immunol |
| Volume | 161 |
| Pagination | 241-50 |
| Date Published | Dec |
| ISBN Number | 1521-7035 (Electronic)<br/>1521-6616 (Linking) |
| Accession Number | 26235378 |
| Keywords | Adaptor Proteins, Signal Transducing/genetics/*immunology, Antibodies, Antinuclear/blood/*immunology, Antibody Specificity/*immunology, Cell Line, Tumor, Humans, Immunoblotting, Methyl-CpG-Binding Protein 2/*immunology, Microscopy, Confocal, Protein Binding/immunology, RNA Interference, Transcription Factors/genetics/*immunology |
| Abstract | Human antinuclear autoantibodies (ANAs) targeting the dense fine speckled (DFS) nuclear protein DFS70, commonly known as lens epithelium derived growth factor p75 (LEDGFp75), present a clinical puzzle since their significance remains elusive. While their frequencies are low in ANA-positive autoimmune rheumatic diseases, they are relatively elevated in clinical laboratory referrals, diverse inflammatory conditions, and 'apparently' healthy individuals. We reported previously that DFS70/LEDGFp75 is an autoantigen in prostate cancer that closely interacts with another 70kD DFS nuclear protein, methyl CpG binding protein 2 (MeCP2). This led us to investigate if anti-DFS sera exclusively target DFS70/LEDGFp75 or also recognize MeCP2. Using several complementary autoantibody detection platforms and cellular/molecular approaches we evaluated 65 human sera producing anti-DFS autoantibodies. Our results show that these antibodies are highly specific for DFS70/LEDGFp75 and do not target MeCP2. Establishing the specificity of anti-DFS autoantibodies has implications for increasing our understanding of their biological significance and clinical utility. |
| Short Title | Clinical immunologyClinical immunology |
| Alternate Journal | Clinical immunology |
